Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis KAV Study
NCT01570608Phase 3Completed
- Sponsor
- Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
- Start
- Mar 2007
- Primary completion
- Aug 2011
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in exudative macular degeneration, sponsored by Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery. Started Mar 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT01570608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01570608.